10x Science GTM brain

10x Science develops AI software for protein therapeutic characterization for biopharma and research teams.

category

AI protein characterization

market profile

  • text: Biologic drug developers face manual analytical bottlenecks as discovery produces more candidates.
  • text: Established mass spectrometry informatics vendors offer biotherapeutic characterization workflows, making validation and interoperability important to adoption.

personas

  • title: Head of analytical development at a biopharma company
    pains:
    • Manual interpretation and report generation slow candidate progression.
    • Scientific reproducibility and analytical confidence must be maintained while throughput increases.
  • title: Mass spectrometry or proteomics core director
    pains:
    • Expert analysts spend substantial time processing large spectral datasets.
    • Scaling sample volume can require hiring scarce specialists.
  • title: Biotech R&D leader
    pains:
    • Promising biologics cannot progress until molecular characterization is complete.
    • Limited research capacity makes it difficult to triage an expanding candidate pipeline.

icp

  • text: Pharmaceutical and biotech organizations developing protein therapeutics, including antibodies and engineered proteins.
  • text: Academic proteomics core facilities and CROs processing protein characterization data are additional prospective accounts.
  • text: Enterprise pharma is an explicitly stated target; employee count and contract thresholds are not public.

message pillars

  • text: Modernize the characterization step that constrains drug development.
  • text: Reduce the time spent analyzing data and producing reports.
  • text: Scale analytical throughput without matching increases in headcount.

objections

  • objection: Can AI results be trusted for consequential development decisions?
    response: Compare results against established methods on blinded samples and assess explainability and reproducibility before expansion.
  • objection: Will the platform fit our instruments and analytical workflows?
    response: Confirm supported input formats, instruments and validation requirements in a scoped pilot; these details are not public here.
  • objection: What is the return on a new characterization platform?
    response: Benchmark analysis time and scientist review effort on a representative candidate set against the current process.

competitors

  • name: Genedata
    website: https://www.genedata.com/platform/expressionist
    why: Expressionist supports enterprise mass spectrometry analysis and biotherapeutic characterization.
  • name: Protein Metrics
    website: https://www.proteinmetrics.com/products/byos
    why: Byos analyzes mass spectrometry data for biotherapeutic protein characterization.

influencers

  • name: Andrew Reiter
    url: https://www.linkedin.com/posts/andrew-h-reiter_im-thrilled-to-announce-that-10x-science-activity-7416871669878796288-Rpys
    why: Co-founder writes publicly about modernizing protein characterization.

keywords

  • protein characterization software
  • biotherapeutic mass spectrometry analysis
  • protein therapeutic characterization
  • automated proteomics analysis
  • biologics analytical development
  • mass spectrometry data analysis

voice

  • Scientific and technically ambitious
  • Founder-led and mission-oriented

signals

  • text: A pharma or biotech team is expanding biologics candidates and hiring analytical development scientists.
  • text: A CRO or core lab is increasing mass spectrometry throughput and experiencing analysis backlogs.

hiring

  • Founding Engineer

pricing

model: unknown

motion

sales_led

channels

  • founder LinkedIn
  • YC launch
  • press
  • direct customer conversations

confidence

medium

Founders

  • name: David Roberts
    title: Founder/CEO
    role: CEO
    bio: Chemistry postdoc and Damon Runyon Cancer Research Fellow in Prof. Carolyn Bertozzi's lab (2022 Nobel Prize in Chemistry) at Stanford University. Next-generation scientific leader in chemical biology and glycobiology with 1800+ citations & h-index 23. Received my B.S. double major in chemistry & mathematics at UC San Diego (2016) and Ph.D. in materials chemistry & analytical chemistry at the University of Wisconsin-Madison (2023).
  • name: Andrew Reiter
    title: Founder/COO
    role: COO
    bio: Previously received my B.S. in Biology from UNC-Chapel Hill. I then joined Dr. Steven Carr’s Proteomics Platform Lab at the Broad Institute of MIT and Harvard, where I developed new methods in mass spectrometry. I later became a Ph.D. student and NSF-GRFP fellow in the Department of Biology at Stanford University, where I was co-advised by Dr. Carolyn Bertozzi (2022 Nobel Laureate in Chemistry) and Dr. Or Gozani.
  • name: Vishnu Tejus
    title: Founder/CTO
    role: CTO
    bio: I am a 2x YC Founder. Previously, I built AI for go-to-market teams as the 2nd hire and founding engineer at Nooks. Then, I forward deployed myself in research labs at the University of Washington, UCSF, and Stanford, where I was mentored by world-renowned scientists in analytical chemistry and cancer research. In < 1 year, I published 2 papers and won 4 national awards. Now, I'm building ultrafast AI models for drug discovery teams to characterize proteins and pharmaceutical candidates.

Back to YC companies